CA2465304A1 - Composotions comprenant des inhibiteurs de la voie de signalisation de notch pour la modulation du systeme immunitaire - Google Patents
Composotions comprenant des inhibiteurs de la voie de signalisation de notch pour la modulation du systeme immunitaire Download PDFInfo
- Publication number
- CA2465304A1 CA2465304A1 CA002465304A CA2465304A CA2465304A1 CA 2465304 A1 CA2465304 A1 CA 2465304A1 CA 002465304 A CA002465304 A CA 002465304A CA 2465304 A CA2465304 A CA 2465304A CA 2465304 A1 CA2465304 A1 CA 2465304A1
- Authority
- CA
- Canada
- Prior art keywords
- notch
- polypeptide
- protein
- notch ligand
- domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000003112 inhibitor Substances 0.000 title claims abstract description 197
- 230000005913 Notch signaling pathway Effects 0.000 title claims abstract description 122
- 210000000987 immune system Anatomy 0.000 title claims description 30
- 239000000203 mixture Substances 0.000 title claims description 22
- 238000004519 manufacturing process Methods 0.000 claims abstract description 37
- 239000003814 drug Substances 0.000 claims abstract description 32
- 230000003308 immunostimulating effect Effects 0.000 claims abstract description 10
- 229960001438 immunostimulant agent Drugs 0.000 claims abstract description 9
- 239000003022 immunostimulating agent Substances 0.000 claims abstract description 9
- 102000005650 Notch Receptors Human genes 0.000 claims description 786
- 108010070047 Notch Receptors Proteins 0.000 claims description 786
- 239000003446 ligand Substances 0.000 claims description 514
- 108090000623 proteins and genes Proteins 0.000 claims description 462
- 102000004169 proteins and genes Human genes 0.000 claims description 438
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 435
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 426
- 229920001184 polypeptide Polymers 0.000 claims description 424
- 102000040430 polynucleotide Human genes 0.000 claims description 246
- 108091033319 polynucleotide Proteins 0.000 claims description 246
- 239000002157 polynucleotide Substances 0.000 claims description 245
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 171
- 238000000034 method Methods 0.000 claims description 144
- 230000011664 signaling Effects 0.000 claims description 134
- 239000000427 antigen Substances 0.000 claims description 84
- 108091007433 antigens Proteins 0.000 claims description 84
- 102000036639 antigens Human genes 0.000 claims description 84
- 102000012545 EGF-like domains Human genes 0.000 claims description 80
- 108050002150 EGF-like domains Proteins 0.000 claims description 80
- 230000014509 gene expression Effects 0.000 claims description 80
- 244000052769 pathogen Species 0.000 claims description 70
- 230000001717 pathogenic effect Effects 0.000 claims description 70
- 230000000890 antigenic effect Effects 0.000 claims description 68
- 239000000178 monomer Substances 0.000 claims description 65
- 239000003795 chemical substances by application Substances 0.000 claims description 56
- 210000004027 cell Anatomy 0.000 claims description 51
- 102100033237 Pro-epidermal growth factor Human genes 0.000 claims description 45
- 230000003993 interaction Effects 0.000 claims description 42
- 230000000694 effects Effects 0.000 claims description 40
- 241000282414 Homo sapiens Species 0.000 claims description 36
- 239000012634 fragment Substances 0.000 claims description 36
- 230000001965 increasing effect Effects 0.000 claims description 36
- 102100036466 Delta-like protein 3 Human genes 0.000 claims description 34
- 102000049546 Jagged-2 Human genes 0.000 claims description 27
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 27
- 230000027455 binding Effects 0.000 claims description 24
- 208000015181 infectious disease Diseases 0.000 claims description 19
- 239000008194 pharmaceutical composition Substances 0.000 claims description 19
- 102000011842 Serrate-Jagged Proteins Human genes 0.000 claims description 18
- 108010036039 Serrate-Jagged Proteins Proteins 0.000 claims description 18
- 230000004936 stimulating effect Effects 0.000 claims description 18
- 230000002401 inhibitory effect Effects 0.000 claims description 17
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 16
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 16
- 230000002222 downregulating effect Effects 0.000 claims description 16
- 230000028993 immune response Effects 0.000 claims description 16
- 101000994437 Homo sapiens Protein jagged-1 Proteins 0.000 claims description 15
- 101000994434 Homo sapiens Protein jagged-2 Proteins 0.000 claims description 15
- 108060003951 Immunoglobulin Proteins 0.000 claims description 15
- 206010028980 Neoplasm Diseases 0.000 claims description 15
- 239000005557 antagonist Substances 0.000 claims description 15
- 102000056036 human JAG1 Human genes 0.000 claims description 15
- 102000018358 immunoglobulin Human genes 0.000 claims description 15
- 101710112748 Delta-like protein 3 Proteins 0.000 claims description 14
- 101000978766 Homo sapiens Neurogenic locus notch homolog protein 1 Proteins 0.000 claims description 14
- 102000045609 human NOTCH1 Human genes 0.000 claims description 14
- 230000001603 reducing effect Effects 0.000 claims description 14
- 101000577199 Homo sapiens Neurogenic locus notch homolog protein 2 Proteins 0.000 claims description 13
- 210000003289 regulatory T cell Anatomy 0.000 claims description 12
- 238000011282 treatment Methods 0.000 claims description 12
- 101710170213 Protein jagged-2 Proteins 0.000 claims description 11
- 230000004048 modification Effects 0.000 claims description 11
- 238000012986 modification Methods 0.000 claims description 11
- 229960005486 vaccine Drugs 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 10
- 238000002255 vaccination Methods 0.000 claims description 10
- 239000013598 vector Substances 0.000 claims description 9
- 102000049556 Jagged-1 Human genes 0.000 claims description 8
- 108700003486 Jagged-1 Proteins 0.000 claims description 8
- 241000894006 Bacteria Species 0.000 claims description 7
- 108700037966 Protein jagged-1 Proteins 0.000 claims description 7
- 239000011230 binding agent Substances 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 7
- 230000001506 immunosuppresive effect Effects 0.000 claims description 7
- 208000035473 Communicable disease Diseases 0.000 claims description 6
- 206010062016 Immunosuppression Diseases 0.000 claims description 6
- 239000002671 adjuvant Substances 0.000 claims description 6
- 230000002708 enhancing effect Effects 0.000 claims description 6
- 230000003612 virological effect Effects 0.000 claims description 6
- 230000001580 bacterial effect Effects 0.000 claims description 5
- 230000006058 immune tolerance Effects 0.000 claims description 5
- 231100000433 cytotoxic Toxicity 0.000 claims description 4
- 230000001472 cytotoxic effect Effects 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 230000002538 fungal effect Effects 0.000 claims description 3
- 230000003071 parasitic effect Effects 0.000 claims description 3
- 241000124008 Mammalia Species 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 108700041286 delta Proteins 0.000 claims description 2
- 239000013604 expression vector Substances 0.000 claims description 2
- 230000036039 immunity Effects 0.000 claims description 2
- 229940021993 prophylactic vaccine Drugs 0.000 claims description 2
- 229940021747 therapeutic vaccine Drugs 0.000 claims description 2
- 101000928537 Homo sapiens Delta-like protein 1 Proteins 0.000 claims 20
- 101000928513 Homo sapiens Delta-like protein 3 Proteins 0.000 claims 20
- 101000872077 Homo sapiens Delta-like protein 4 Proteins 0.000 claims 20
- 101000577202 Homo sapiens Neurogenic locus notch homolog protein 3 Proteins 0.000 claims 12
- 101000577163 Homo sapiens Neurogenic locus notch homolog protein 4 Proteins 0.000 claims 12
- 208000037581 Persistent Infection Diseases 0.000 claims 1
- 210000003162 effector t lymphocyte Anatomy 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 230000001681 protective effect Effects 0.000 claims 1
- 239000002464 receptor antagonist Substances 0.000 claims 1
- 229940044551 receptor antagonist Drugs 0.000 claims 1
- 239000012646 vaccine adjuvant Substances 0.000 abstract 1
- 229940124931 vaccine adjuvant Drugs 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 description 192
- 239000002773 nucleotide Substances 0.000 description 47
- 125000003729 nucleotide group Chemical group 0.000 description 47
- 108091028043 Nucleic acid sequence Proteins 0.000 description 39
- 235000001014 amino acid Nutrition 0.000 description 36
- 229940024606 amino acid Drugs 0.000 description 34
- 150000007523 nucleic acids Chemical class 0.000 description 34
- 150000001413 amino acids Chemical class 0.000 description 33
- 230000004913 activation Effects 0.000 description 25
- 108020004414 DNA Proteins 0.000 description 24
- 102000039446 nucleic acids Human genes 0.000 description 19
- 108020004707 nucleic acids Proteins 0.000 description 19
- 102000004127 Cytokines Human genes 0.000 description 18
- 108090000695 Cytokines Proteins 0.000 description 18
- 108020004705 Codon Proteins 0.000 description 17
- 230000003834 intracellular effect Effects 0.000 description 17
- 238000003752 polymerase chain reaction Methods 0.000 description 17
- 150000001875 compounds Chemical class 0.000 description 16
- 238000009396 hybridization Methods 0.000 description 15
- 239000000523 sample Substances 0.000 description 14
- 101710189714 Major cell-binding factor Proteins 0.000 description 13
- 108010050254 Presenilins Proteins 0.000 description 13
- 102000015499 Presenilins Human genes 0.000 description 13
- 102100030000 Recombining binding protein suppressor of hairless Human genes 0.000 description 13
- 230000006870 function Effects 0.000 description 11
- 230000005764 inhibitory process Effects 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 238000006467 substitution reaction Methods 0.000 description 11
- 108020001507 fusion proteins Proteins 0.000 description 10
- 102000037865 fusion proteins Human genes 0.000 description 10
- 239000011159 matrix material Substances 0.000 description 10
- 102000005962 receptors Human genes 0.000 description 10
- 108020003175 receptors Proteins 0.000 description 10
- 102000001760 Notch3 Receptor Human genes 0.000 description 9
- 108010029756 Notch3 Receptor Proteins 0.000 description 9
- 108010029741 Notch4 Receptor Proteins 0.000 description 9
- 102000001753 Notch4 Receptor Human genes 0.000 description 9
- 239000002299 complementary DNA Substances 0.000 description 9
- 108010049777 Ankyrins Proteins 0.000 description 8
- 102000008102 Ankyrins Human genes 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- 210000003719 b-lymphocyte Anatomy 0.000 description 8
- 229940088598 enzyme Drugs 0.000 description 8
- 210000004940 nucleus Anatomy 0.000 description 8
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 description 7
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 description 7
- 102000001756 Notch2 Receptor Human genes 0.000 description 7
- 108010029751 Notch2 Receptor Proteins 0.000 description 7
- 238000010367 cloning Methods 0.000 description 7
- 125000004122 cyclic group Chemical group 0.000 description 7
- 238000012217 deletion Methods 0.000 description 7
- 230000037430 deletion Effects 0.000 description 7
- 230000001419 dependent effect Effects 0.000 description 7
- 230000006337 proteolytic cleavage Effects 0.000 description 7
- 230000019491 signal transduction Effects 0.000 description 7
- 101000584736 Ciona intestinalis Suppressor of hairless homolog Proteins 0.000 description 6
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 6
- 101100118545 Holotrichia diomphalia EGF-like gene Proteins 0.000 description 6
- 101000801209 Homo sapiens Transducin-like enhancer protein 4 Proteins 0.000 description 6
- 108090000176 Interleukin-13 Proteins 0.000 description 6
- 102000000743 Interleukin-5 Human genes 0.000 description 6
- 108010002616 Interleukin-5 Proteins 0.000 description 6
- 108020004511 Recombinant DNA Proteins 0.000 description 6
- 108700012920 TNF Proteins 0.000 description 6
- 210000000612 antigen-presenting cell Anatomy 0.000 description 6
- 230000000295 complement effect Effects 0.000 description 6
- 238000003780 insertion Methods 0.000 description 6
- 230000037431 insertion Effects 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 230000008685 targeting Effects 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 5
- 102000035195 Peptidases Human genes 0.000 description 5
- 108091005804 Peptidases Proteins 0.000 description 5
- 239000004365 Protease Substances 0.000 description 5
- 102100033763 Transducin-like enhancer protein 4 Human genes 0.000 description 5
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 5
- 238000007792 addition Methods 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 238000003776 cleavage reaction Methods 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 239000003623 enhancer Substances 0.000 description 5
- 125000001183 hydrocarbyl group Chemical group 0.000 description 5
- 210000002865 immune cell Anatomy 0.000 description 5
- 210000004962 mammalian cell Anatomy 0.000 description 5
- 230000007017 scission Effects 0.000 description 5
- 238000002864 sequence alignment Methods 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 4
- 101100510615 Caenorhabditis elegans lag-2 gene Proteins 0.000 description 4
- 101150092640 HES1 gene Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 101100284799 Mus musculus Hesx1 gene Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 230000001086 cytosolic effect Effects 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- -1 lFNy Proteins 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 238000010369 molecular cloning Methods 0.000 description 4
- 150000002894 organic compounds Chemical class 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 235000019419 proteases Nutrition 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 238000010561 standard procedure Methods 0.000 description 4
- 125000001424 substituent group Chemical group 0.000 description 4
- 238000013519 translation Methods 0.000 description 4
- 230000014616 translation Effects 0.000 description 4
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 3
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 3
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 3
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 3
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 3
- 102000016970 Follistatin Human genes 0.000 description 3
- 108010014612 Follistatin Proteins 0.000 description 3
- 102000000588 Interleukin-2 Human genes 0.000 description 3
- 108010002350 Interleukin-2 Proteins 0.000 description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
- 101800001628 Notch 1 intracellular domain Proteins 0.000 description 3
- 102400000552 Notch 1 intracellular domain Human genes 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 102000040945 Transcription factor Human genes 0.000 description 3
- 108091023040 Transcription factor Proteins 0.000 description 3
- 101001124893 Xenopus laevis Nodal homolog 3-A Proteins 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 230000000692 anti-sense effect Effects 0.000 description 3
- 235000009582 asparagine Nutrition 0.000 description 3
- 229960001230 asparagine Drugs 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 229940112869 bone morphogenetic protein Drugs 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 102000006533 chordin Human genes 0.000 description 3
- 108010008846 chordin Proteins 0.000 description 3
- 108091036078 conserved sequence Proteins 0.000 description 3
- 230000003828 downregulation Effects 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 210000005260 human cell Anatomy 0.000 description 3
- 230000036737 immune function Effects 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 108700007229 noggin Proteins 0.000 description 3
- 102000045246 noggin Human genes 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 235000004400 serine Nutrition 0.000 description 3
- 238000002741 site-directed mutagenesis Methods 0.000 description 3
- 229910001415 sodium ion Inorganic materials 0.000 description 3
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 108091006106 transcriptional activators Proteins 0.000 description 3
- 238000010361 transduction Methods 0.000 description 3
- 230000026683 transduction Effects 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- UBWXUGDQUBIEIZ-UHFFFAOYSA-N (13-methyl-3-oxo-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-17-yl) 3-phenylpropanoate Chemical compound CC12CCC(C3CCC(=O)C=C3CC3)C3C1CCC2OC(=O)CCC1=CC=CC=C1 UBWXUGDQUBIEIZ-UHFFFAOYSA-N 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- 108010059616 Activins Proteins 0.000 description 2
- 102000005606 Activins Human genes 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102000018720 Basic Helix-Loop-Helix Transcription Factors Human genes 0.000 description 2
- 108010027344 Basic Helix-Loop-Helix Transcription Factors Proteins 0.000 description 2
- 108010040422 Bone Morphogenetic Protein Receptors Proteins 0.000 description 2
- 102000001893 Bone Morphogenetic Protein Receptors Human genes 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 241000699662 Cricetomys gambianus Species 0.000 description 2
- 230000004568 DNA-binding Effects 0.000 description 2
- 108010003661 Distal-less homeobox proteins Proteins 0.000 description 2
- 101100015729 Drosophila melanogaster drk gene Proteins 0.000 description 2
- 101150113929 EBNA2 gene Proteins 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 108700023372 Glycosyltransferases Proteins 0.000 description 2
- 102000051366 Glycosyltransferases Human genes 0.000 description 2
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 description 2
- 102100025169 Max-binding protein MNT Human genes 0.000 description 2
- UIQMVEYFGZJHCZ-SSTWWWIQSA-N Nalorphine Chemical compound C([C@@H](N(CC1)CC=C)[C@@H]2C=C[C@@H]3O)C4=CC=C(O)C5=C4[C@@]21[C@H]3O5 UIQMVEYFGZJHCZ-SSTWWWIQSA-N 0.000 description 2
- 108700037638 Neurogenic locus notch homolog protein 1 Proteins 0.000 description 2
- 102100023181 Neurogenic locus notch homolog protein 1 Human genes 0.000 description 2
- 102000015636 Oligopeptides Human genes 0.000 description 2
- 108010038807 Oligopeptides Proteins 0.000 description 2
- 102000012412 Presenilin-1 Human genes 0.000 description 2
- 108010036933 Presenilin-1 Proteins 0.000 description 2
- 102000012419 Presenilin-2 Human genes 0.000 description 2
- 108010036908 Presenilin-2 Proteins 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 101000930762 Sulfolobus acidocaldarius (strain ATCC 33909 / DSM 639 / JCM 8929 / NBRC 15157 / NCIMB 11770) Signal recognition particle receptor FtsY Proteins 0.000 description 2
- 230000005867 T cell response Effects 0.000 description 2
- 210000000447 Th1 cell Anatomy 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 102000002689 Toll-like receptor Human genes 0.000 description 2
- 108020000411 Toll-like receptor Proteins 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000000488 activin Substances 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000005754 cellular signaling Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000012411 cloning technique Methods 0.000 description 2
- 238000004590 computer program Methods 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000007877 drug screening Methods 0.000 description 2
- 239000000428 dust Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 101150098203 grb2 gene Proteins 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 238000013537 high throughput screening Methods 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 230000000873 masking effect Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 230000008689 nuclear function Effects 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 239000000816 peptidomimetic Substances 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- 125000003367 polycyclic group Chemical group 0.000 description 2
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000007781 signaling event Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 235000008521 threonine Nutrition 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 108091006107 transcriptional repressors Proteins 0.000 description 2
- 230000029069 type 2 immune response Effects 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 235000002374 tyrosine Nutrition 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- OIXLLKLZKCBCPS-RZVRUWJTSA-N (2s)-2-azanyl-5-[bis(azanyl)methylideneamino]pentanoic acid Chemical compound OC(=O)[C@@H](N)CCCNC(N)=N.OC(=O)[C@@H](N)CCCNC(N)=N OIXLLKLZKCBCPS-RZVRUWJTSA-N 0.000 description 1
- PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 description 1
- YVOOPGWEIRIUOX-UHFFFAOYSA-N 2-azanyl-3-sulfanyl-propanoic acid Chemical compound SCC(N)C(O)=O.SCC(N)C(O)=O YVOOPGWEIRIUOX-UHFFFAOYSA-N 0.000 description 1
- 108020005065 3' Flanking Region Proteins 0.000 description 1
- 108020005029 5' Flanking Region Proteins 0.000 description 1
- 108010022579 ATP dependent 26S protease Proteins 0.000 description 1
- 208000035657 Abasia Diseases 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 230000003844 B-cell-activation Effects 0.000 description 1
- 101150075764 CD4 gene Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 108010069514 Cyclic Peptides Proteins 0.000 description 1
- 102000001189 Cyclic Peptides Human genes 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 238000007399 DNA isolation Methods 0.000 description 1
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 1
- 101710096438 DNA-binding protein Proteins 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 102000004648 Distal-less homeobox proteins Human genes 0.000 description 1
- 241000244160 Echinococcus Species 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102100021186 Granulysin Human genes 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 101150094793 Hes3 gene Proteins 0.000 description 1
- 101150029234 Hes5 gene Proteins 0.000 description 1
- 101001040751 Homo sapiens Granulysin Proteins 0.000 description 1
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108700003489 Jagged-2 Proteins 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical group C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- NVGBPTNZLWRQSY-UWVGGRQHSA-N Lys-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CCCCN NVGBPTNZLWRQSY-UWVGGRQHSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 102000043131 MHC class II family Human genes 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 101710167839 Morphogenetic protein Proteins 0.000 description 1
- 101000686985 Mouse mammary tumor virus (strain C3H) Protein PR73 Proteins 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101100016883 Mus musculus Hes1 gene Proteins 0.000 description 1
- 101001003232 Mus musculus Immediate early response gene 2 protein Proteins 0.000 description 1
- XNZHJADQXXCSFV-OCCSQVGLSA-N N-[2-[[(2S)-3-methyl-1-[[(2S)-3-methyl-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]amino]-2-oxoethyl]carbamic acid tert-butyl ester Chemical compound CC(C)[C@@H](C=O)NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)OC(C)(C)C XNZHJADQXXCSFV-OCCSQVGLSA-N 0.000 description 1
- 102100025246 Neurogenic locus notch homolog protein 2 Human genes 0.000 description 1
- 108700037064 Neurogenic locus notch homolog protein 2 Proteins 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 241001495084 Phylo Species 0.000 description 1
- 241000224016 Plasmodium Species 0.000 description 1
- 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
- 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 101710087037 Protein deltex Proteins 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 1
- 230000029662 T-helper 1 type immune response Effects 0.000 description 1
- 210000004241 Th2 cell Anatomy 0.000 description 1
- 241000223996 Toxoplasma Species 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 description 1
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000006287 biotinylation Effects 0.000 description 1
- 238000007413 biotinylation Methods 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000006041 cell recruitment Effects 0.000 description 1
- 230000023549 cell-cell signaling Effects 0.000 description 1
- 238000010382 chemical cross-linking Methods 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 230000003081 coactivator Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 238000007878 drug screening assay Methods 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000001215 fluorescent labelling Methods 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 235000004554 glutamine Nutrition 0.000 description 1
- 108700014210 glycosyltransferase activity proteins Proteins 0.000 description 1
- 210000002288 golgi apparatus Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 244000000013 helminth Species 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 102000046883 human NOTCH2 Human genes 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 208000003747 lymphoid leukemia Diseases 0.000 description 1
- 108010054155 lysyllysine Proteins 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 102000035118 modified proteins Human genes 0.000 description 1
- 108091005573 modified proteins Proteins 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- 210000004898 n-terminal fragment Anatomy 0.000 description 1
- AEMBWNDIEFEPTH-UHFFFAOYSA-N n-tert-butyl-n-ethylnitrous amide Chemical compound CCN(N=O)C(C)(C)C AEMBWNDIEFEPTH-UHFFFAOYSA-N 0.000 description 1
- 210000004318 naive thymus-derived CD4-positive, alpha-beta T lymphocyte Anatomy 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 235000008729 phenylalanine Nutrition 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000010399 physical interaction Effects 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 108010040003 polyglutamine Proteins 0.000 description 1
- 229920000155 polyglutamine Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 238000010845 search algorithm Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 208000002491 severe combined immunodeficiency Diseases 0.000 description 1
- 230000003584 silencer Effects 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 231100000617 superantigen Toxicity 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000012622 synthetic inhibitor Substances 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- LZMSXDHGHZKXJD-VJANTYMQSA-N trypanothione disulfide Chemical group OC(=O)[C@@H](N)CCC(=O)N[C@H]1CSSC[C@H](NC(=O)CC[C@H](N)C(O)=O)C(=O)NCC(=O)NCCCNCCCCNC(=O)CNC1=O LZMSXDHGHZKXJD-VJANTYMQSA-N 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0127267.3 | 2001-11-14 | ||
| GB0127267A GB0127267D0 (en) | 2001-11-14 | 2001-11-14 | Medical treatment |
| PCT/GB2002/003426 WO2003011317A1 (fr) | 2001-07-25 | 2002-07-25 | Modulateurs de signalisation de notch utilises en immunotherapie |
| GBPCT/GB02/03426 | 2002-07-25 | ||
| GB0220849.4 | 2002-09-07 | ||
| GB0220849A GB0220849D0 (en) | 2002-09-07 | 2002-09-07 | Medical treatment |
| GB0220913.8 | 2002-09-10 | ||
| GB0220913A GB0220913D0 (en) | 2002-09-10 | 2002-09-10 | Medical treatment |
| GBPCT/GB02/004390 | 2002-09-27 | ||
| PCT/GB2002/004390 WO2003029293A2 (fr) | 2001-09-28 | 2002-09-27 | Modulateurs |
| PCT/GB2002/005137 WO2003041735A2 (fr) | 2001-11-14 | 2002-11-13 | Traitement medical |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2465304A1 true CA2465304A1 (fr) | 2003-05-22 |
Family
ID=34743273
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002465304A Abandoned CA2465304A1 (fr) | 2001-11-14 | 2002-11-13 | Composotions comprenant des inhibiteurs de la voie de signalisation de notch pour la modulation du systeme immunitaire |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP1446424A2 (fr) |
| JP (1) | JP2005518785A (fr) |
| CA (1) | CA2465304A1 (fr) |
| WO (1) | WO2003041735A2 (fr) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006506322A (ja) * | 2002-04-05 | 2006-02-23 | ロランティス リミテッド | 内科療法 |
| AU2003255735A1 (en) * | 2002-08-03 | 2004-02-23 | Lorantis Limited | Conjugate of notch signalling pathway modulators and their use in medical treatment |
| WO2004024764A1 (fr) * | 2002-09-10 | 2004-03-25 | Lorantis Limited | Composition pharmaceutique et traitements medicaux comprenant des proteines a ligand notch |
| WO2004060262A2 (fr) * | 2003-01-07 | 2004-07-22 | Lorantis Limited | Traitement medical |
| US7906116B2 (en) | 2005-09-01 | 2011-03-15 | Parkash Gill | Methods for using and identifying modulators of Delta-like 4 |
| WO2011053822A2 (fr) | 2009-11-01 | 2011-05-05 | The Brigham And Women's Hospital, Inc. | Inhibition de notch pour le traitement et la prévention de l'obésité et du syndrome métabolique |
| US9567396B2 (en) | 2006-03-07 | 2017-02-14 | Evonik Degussa Gmbh | Notch inhibition in the prevention of vein graft failure |
| US8133857B2 (en) | 2006-03-07 | 2012-03-13 | The Brigham and Women's FHospital, Inc. | NOTCH inhibition in the treatment of atherosclerosis |
| SI2066694T1 (sl) | 2006-09-29 | 2016-02-29 | Oncomed Pharmaceuticals, Inc. | Sestavki in postopki za diagnosticiranje in zdravljenje raka |
| CL2007003661A1 (es) * | 2006-12-18 | 2008-07-18 | Genentech Inc | Regiones de cadena pesada variable y liviana variable; acidos nucleicos que las codifican; metodo de produccion; anticuerpos anti-notch3 que las comprenden; y uso de los anticuerpos para tratar enfermedades relacionadas con el receptor notch3. |
| US8883145B2 (en) | 2009-10-16 | 2014-11-11 | Oncomed Pharmaceuticals, Inc. | Methods of treatment with DLL4 antagonists and an anti-hypertensive agent |
| US8551479B2 (en) | 2010-09-10 | 2013-10-08 | Oncomed Pharmaceuticals, Inc. | Methods for treating melanoma |
| HUE042192T2 (hu) | 2011-09-23 | 2019-06-28 | Oncomed Pharm Inc | VEGF/DLL4-kötõ ágensek és alkalmazásaik |
| JP6371294B2 (ja) | 2012-10-31 | 2018-08-08 | オンコメッド ファーマシューティカルズ インコーポレイテッド | Ｄｌｌ４アンタゴニストによる処置の方法およびモニタリング |
| TW201431880A (zh) | 2012-11-07 | 2014-08-16 | Pfizer | 抗切口３（ａｎｔｉ－ｎｏｔｃｈ３）抗體及抗體－藥物共軛體 |
| WO2016070051A2 (fr) | 2014-10-31 | 2016-05-06 | Oncomed Pharmaceuticals, Inc. | Thérapie combinée pour le traitement d'une maladie |
| JP6967003B2 (ja) | 2015-09-23 | 2021-11-17 | メレオ バイオファーマ ５ インコーポレイテッド | がんの処置のための方法および組成物 |
| US20210290633A1 (en) | 2018-07-19 | 2021-09-23 | INSERM (Insstitut National de la Santé et de la Recherche Médicale) | Combination for treating cancer |
| WO2022101481A1 (fr) | 2020-11-16 | 2022-05-19 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Procédés et compositions permettant de prédire et traiter le mélanome uvéal |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5786158A (en) * | 1992-04-30 | 1998-07-28 | Yale University | Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids |
| JP3922726B2 (ja) * | 1996-07-16 | 2007-05-30 | 旭化成株式会社 | 分化抑制剤 |
| AU1054900A (en) * | 1998-10-30 | 2000-05-22 | Smith & Nephew Plc | Compositions comprising notch receptor manipulating agents |
| JP2003507029A (ja) * | 1999-08-19 | 2003-02-25 | カイロン コーポレイション | Ｎｏｔｃｈレセプターリガンドおよびその使用 |
| US20020151487A1 (en) * | 2000-08-31 | 2002-10-17 | Loyola University Chicago | Method and reagents for epithelial barrier formation and treatment of malignant and benign skin disorders by modulating the notch pathway |
| GB0123379D0 (en) * | 2001-09-28 | 2001-11-21 | Lorantis Ltd | Modulators |
-
2002
- 2002-11-13 JP JP2003543622A patent/JP2005518785A/ja active Pending
- 2002-11-13 CA CA002465304A patent/CA2465304A1/fr not_active Abandoned
- 2002-11-13 EP EP02779679A patent/EP1446424A2/fr not_active Withdrawn
- 2002-11-13 WO PCT/GB2002/005137 patent/WO2003041735A2/fr active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| JP2005518785A (ja) | 2005-06-30 |
| WO2003041735A3 (fr) | 2003-09-25 |
| EP1446424A2 (fr) | 2004-08-18 |
| WO2003041735A2 (fr) | 2003-05-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20050137130A1 (en) | Medical treatment | |
| US20050026831A1 (en) | Medical treatment | |
| Kowalczyk et al. | Self-adjuvanted mRNA vaccines induce local innate immune responses that lead to a potent and boostable adaptive immunity | |
| CA2465304A1 (fr) | Composotions comprenant des inhibiteurs de la voie de signalisation de notch pour la modulation du systeme immunitaire | |
| CN107074967B (zh) | 白介素-2/白介素-2受体α融合蛋白和使用方法 | |
| US20050261477A1 (en) | Pharmaceutical compositions and medical treatments comprising notch ligand proteins | |
| US20060002924A1 (en) | Conjugate of notch signalling pathway modulators and their use in medical treatment | |
| US20060084588A1 (en) | Modulation of immune function | |
| JP7004761B2 (ja) | 癌治療のための改善された細胞組成物および方法 | |
| US20100303867A1 (en) | a composition comprising a notch ligand and an allergenb or allergen bystander antigen | |
| US20210283242A1 (en) | Immune-mediated coronavirus treatments | |
| US20060121030A1 (en) | Use of cd 137 antagonists for the treatment of tumors | |
| US20060003927A1 (en) | Modulation of immune function | |
| WO2004073732A1 (fr) | Modulateurs de la signalisation notch et de l'activite de costimulation de cellules immunitaires utiles en immunotherapie | |
| CN1639569B (zh) | 诱导免疫应答的方法和组合物 | |
| KR20240019135A (ko) | 작제물과 면역자극 화합물의 공동발현 | |
| AU2002343019A1 (en) | Composition comprising inhibitors of the notch signalling pathway for the modulation of the immune system | |
| US20120315290A1 (en) | Inhibitors of ll-37 mediated immune reactivity to self nucleic acids | |
| WO2004087195A2 (fr) | Dosages et traitements medicaux | |
| JP2008120740A (ja) | Ｃｄ８ｔ細胞活性化抑制剤、それを用いたリウマチ治療薬およびリウマチ治療用ｄｎａワクチン | |
| US20080267964A1 (en) | Synergistic Effect of Tgf-Beta Blockade and Immunogenic Agents on Tumors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |